IL-17A Can Promote -Induced Sarcoidosis-Like Granulomatosis in Mice
Overview
Authors
Affiliations
The etiology of sarcoidosis is unknown. In this study, (PA) was used to induce sarcoidosis-like granulomatous inflammation in a mouse model. Wild-Type (WT) C57BL/6 mice were divided into three groups: (1) WT-PA group; (2) WT-PA + Incomplete Freund's Adjuvant (IFA) group; and (3) WT-PBS group. Loose granuloma formation was observed in the lungs on day 56 in the WT-PA and WT-PA + IFA groups. The proportions of peripheral Th17 cells in the WT-PA ( = 0.0004) and WT-PA + IFA groups ( = 0.0005) were significantly higher than that in the WT-PBS group. The proportions of peripheral Treg cells in the WT-PA ( < 0.0001) and WT-PA + IFA groups ( < 0.0001) were lower than that in the WT-PBS group. Then, to explore the mechanism of IL-17, Wild-Type (WT) C57BL/6 mice were divided into three groups: (1) WT-PBS group (2) WT-PA group; (3) WT-PA + mouse IL-17A neutralizing antibody (IL-17Ab) group. IL-17A gene knockout mice (KO) were divided into two groups: (1) KO -PA group; (2) KO-PBS group. The KO-PA and WT-PA + IL-17Ab groups showed reduced inflammation and no loose granuloma formation on day 56. As compared to the WT-PA group, the ratio of peripheral Th17 in the KO-PA ( < 0.0001) and WT-PA + IL-17Ab groups ( < 0.0001) decreased, while the ratio of peripheral Treg in the KO-PA ( < 0.0001) and WT-PA + IL-17Ab ( = 0.0069) groups increased on day 56. Hence, PA can be used to establish a mouse model of sarcoidosis-like granuloma. IL-17A plays an important role in experimental sarcoidosis-like granuloma formation.
Shaping Rare Granulomatous Diseases in the Lab: How New Models Are Changing the Game.
Ceccato J, Gualtiero G, Piazza M, Carraro S, Buso H, Felice C Cells. 2025; 14(4).
PMID: 39996765 PMC: 11853845. DOI: 10.3390/cells14040293.
Jiang D, Xiao H, Zheng X, Dong R, Zhang H, Dai H Exp Biol Med (Maywood). 2023; 248(14):1181-1190.
PMID: 37452708 PMC: 10621476. DOI: 10.1177/15353702231182224.
Sarcoid-like Granulomatosis Associated with Immune Checkpoint Inhibitors in Melanoma.
Melin A, Routier E, Roy S, Pradere P, Le Pavec J, Pierre T Cancers (Basel). 2022; 14(12).
PMID: 35740604 PMC: 9221061. DOI: 10.3390/cancers14122937.
Wu J, Imadojemu S, Caplan A Am J Clin Dermatol. 2022; 23(4):499-514.
PMID: 35583850 DOI: 10.1007/s40257-022-00693-0.
Systemic immune response to vimentin and granuloma formation in a model of pulmonary sarcoidosis.
Bagavant H, Cizio K, Araszkiewicz A, Papinska J, Garman L, Li C J Transl Autoimmun. 2022; 5():100153.
PMID: 35434591 PMC: 9006845. DOI: 10.1016/j.jtauto.2022.100153.